Search Stock News and Analysis

https://www.schaeffersresearch.com/content/news/2019/07/29/analyst-this-drug-name-is-a-top-pick

7/29/2019 9:13 AM

Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 1.5% in pre-market trading, after the stock received an upgrade to "top pick" from "outperform" out of RBC. The brokerage firm cited new...

Gilead Sciences Stock Drops After Goldman Says "Sell"

https://www.schaeffersresearch.com/content/news/2019/05/28/gilead-sciences-stock-drops-after-goldman-says-sell

5/28/2019 9:27 AM

Goldman Sachs downgraded Gilead Sciences, Inc. (NASDAQ:GILD) to "sell" from "neutral," and slashed its price target by $10 to $60 -- a discount to last Friday's close at $66.89. The brokerage firm s...

Arthritis Drug Data Powers Galapagos, Gilead Sciences Stock Rallies

https://www.schaeffersresearch.com/content/news/2019/03/29/arthritis-drug-data-powers-galapagos-gilead-sciences-stock-rallies

3/29/2019 10:23 AM

Galapagos NV (NASDAQ:GLPG) and Gilead Sciences, Inc. (NASDAQ:GILD) stocks are higher this morning, after the companies reported positive data for a jointly developed drug to treat moderate-to-severe...

BMO Sets High Price Targets on 2 Drug Stocks

https://www.schaeffersresearch.com/content/news/2019/03/15/bmo-sets-high-price-targets-on-2-drug-stocks

3/15/2019 9:40 AM

Brokerage firm BMO just began coverage on Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD), expecting major upside from both stocks. Let's take a closer look at the bull notes, alon...

Gilead Sciences Set to Test Support After NASH Drug Failed

https://www.schaeffersresearch.com/content/news/2019/02/12/gilead-sciences-set-to-test-support-after-nash-drug-failed

2/12/2019 9:28 AM

The shares of Gilead Sciences, Inc. (NASDAQ:GILD) are down 3.1% in electronic trading, after the biotech said a late-stage trial for its Non-Alcoholic Steatohepatitis (NASH) drug, selonsertib, failed...

PEOPLE ALSO SEARCH FOR